BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17695458)

  • 1. A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer.
    Burkart C; Bokemeyer C; Klump B; Pereira P; Teichmann R; Hartmann JT
    Anticancer Res; 2007; 27(4C):2845-8. PubMed ID: 17695458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
    Ilson DH
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):22-5. PubMed ID: 15685830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
    Ilson DH; Saltz L; Enzinger P; Huang Y; Kornblith A; Gollub M; O'Reilly E; Schwartz G; DeGroff J; Gonzalez G; Kelsen DP
    J Clin Oncol; 1999 Oct; 17(10):3270-5. PubMed ID: 10506629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.
    Lee DH; Kim HT; Han JY; Lee SY; Yoon SJ; Kim HY; Lee JS
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):83-8. PubMed ID: 17468871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
    Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma.
    Poon D; Chowbay B; Cheung YB; Leong SS; Tan EH
    Cancer; 2005 Feb; 103(3):576-81. PubMed ID: 15612023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma.
    Mühr-Wilkenshoff F; Hinkelbein W; Ohnesorge I; Wolf KJ; Riecken EO; Zeitz M; Scherübl H
    Int J Colorectal Dis; 2003 Jul; 18(4):330-4. PubMed ID: 12774248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan, cisplatin, and radiation in esophageal cancer.
    Ilson DH; Minsky B; Kelsen D
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):11-5. PubMed ID: 12109799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
    Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
    Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.
    Irvin WP; Price FV; Bailey H; Gelder M; Rosenbluth R; Durivage HJ; Potkul RK
    Cancer; 1998 Jan; 82(2):328-33. PubMed ID: 9445190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study.
    Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
    Cancer; 2002 Feb; 94(3):641-6. PubMed ID: 11857295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer.
    Ilson DH; Bains M; Kelsen DP; O'Reilly E; Karpeh M; Coit D; Rusch V; Gonen M; Wilson K; Minsky BD
    J Clin Oncol; 2003 Aug; 21(15):2926-32. PubMed ID: 12885811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
    Han JY; Lee DH; Kim HY; Kim EA; Lee JJ; Ju SY; Shin EH; Lee JS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5909-14. PubMed ID: 14676114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy.
    Chun JH; Kim HK; Lee JS; Choi JY; Lee HG; Yoon SM; Choi IJ; Ryu KW; Kim YW; Bae JM
    Jpn J Clin Oncol; 2004 Jan; 34(1):8-13. PubMed ID: 15020657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.
    Langer CJ; Somer R; Litwin S; Feigenberg S; Movsas B; Maiale C; Sherman E; Millenson M; Nicoloau N; Huang C; Treat J
    J Thorac Oncol; 2007 Mar; 2(3):203-9. PubMed ID: 17410043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma.
    Enzinger PC; Kulke MH; Clark JW; Ryan DP; Kim H; Earle CC; Vincitore MM; Michelini AL; Mayer RJ; Fuchs CS
    Dig Dis Sci; 2005 Dec; 50(12):2218-23. PubMed ID: 16416165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study.
    Look KY; Blessing JA; Levenback C; Kohler M; Chafe W; Roman LD
    Gynecol Oncol; 1998 Sep; 70(3):334-8. PubMed ID: 9790784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas.
    Ajani JA; Ilson DH; Kelsen DP
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):55-8. PubMed ID: 8941411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
    Wolff K; Wein A; Reulbach U; Männlein G; Brückl V; Meier C; Ostermeier N; Schwab SA; Horbach T; Hohenberger W; Hahn EG; Boxberger F
    Anticancer Drugs; 2009 Mar; 20(3):165-73. PubMed ID: 19125117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
    Bodurka DC; Levenback C; Wolf JK; Gano J; Wharton JT; Kavanagh JJ; Gershenson DM
    J Clin Oncol; 2003 Jan; 21(2):291-7. PubMed ID: 12525521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.